Valuation: Summit Therapeutics Inc.

Market Cap 9.77B 13.06B 11.71B 10.71B 18.41B 1,228B 18.99B 129B 51.45B 655B 49.02B 47.97B 2,068B P/E 2026 *
-14.5x
P/E 2027 * -15.2x
Enterprise Value 9.51B 12.71B 11.4B 10.42B 17.92B 1,195B 18.48B 126B 50.07B 637B 47.7B 46.68B 2,012B EV / Sales 2026 *
5,548x
EV / Sales 2027 * 232x
Free-Float
19.32%
Yield 2026 *
-
Yield 2027 * -
1 day+15.08%
1 week+1.87%
Current month+1.87%
1 month-4.89%
3 months+16.98%
6 months-9.68%
Current year-6.63%
1 week 14.17
Extreme 14.17
16.43
1 month 14.17
Extreme 14.17
17.59
Current year 12.07
Extreme 12.07
29.23
1 year 12.07
Extreme 12.07
29.23
3 years 1.75
Extreme 1.75
36.91
5 years 0.66
Extreme 0.66
36.91
10 years 0.66
Extreme 0.66
36.91
Manager TitleAgeSince
Chief Executive Officer 55 2022-07-24
Chief Executive Officer 81 2020-03-31
Director of Finance/CFO 48 2024-04-01
Director TitleAgeSince
Chairman 81 2020-01-31
Director/Board Member 48 2019-11-30
Director/Board Member 55 2020-11-10
Date Insider Type Main position Quantity % Market Cap. Importance
10/8/26 Free

Controller/Auditor

100,000 0.0125%
6/4/26 Buy

Chief Executive Officer

100,000 0.0129%
6/4/26 Buy

Chief Executive Officer

100,000 0.0129%
Change 5-day change 1-year change 3-year change Capi.($)
+15.08%+1.87%-10.18%+794.79% 13.06B
-4.83%+3.51%+55.00%+62.02% 66.7B
+0.02%+1.07%+11.72%+74.73% 56.88B
-1.34%+2.98%+25.08%+98.39% 56.53B
+5.09%+9.89%+27.19%+103.27% 46.49B
+2.62%+1.68%+29.16%+36.08% 44.8B
+8.24%+0.51%+215.16%+807.84% 41.59B
-1.86%+10.13%+28.14%+53.61% 35.35B
-2.97%-9.84%+90.91%+61.94% 33.29B
+5.19%+1.62%-39.69%+381.71% 25.1B
Average +2.52%+2.57%+43.25%+247.44% 41.98B
Weighted average by Cap. +1.10%+3.04%+48.03%+185.52%

Financials

2026 *2027 *
Net sales 1.71M 2.29M 2.05M 1.88M 3.23M 215M 3.33M 22.63M 9.03M 115M 8.6M 8.41M 363M 41.52M 55.49M 49.77M 45.49M 78.23M 5.22B 80.7M 548M 219M 2.78B 208M 204M 8.79B
Net income -662M -884M -793M -725M -1.25B -83.13B -1.29B -8.74B -3.48B -44.36B -3.32B -3.25B -140B -707M -945M -847M -775M -1.33B -88.82B -1.37B -9.34B -3.72B -47.39B -3.55B -3.47B -150B
Net Debt -263M -351M -315M -288M -495M -32.99B -510M -3.47B -1.38B -17.6B -1.32B -1.29B -55.58B -138M -185M -166M -151M -260M -17.35B -268M -1.82B -727M -9.26B -693M -678M -29.22B
Projected Income Statement - Annual - Summit Therapeutics Inc.
Logo Summit Therapeutics Inc.
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician, caregiver and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. Its lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. Ivonescimab is being developed by both Akeso and the Company in multiple Phase III clinical trials. It is also developing ivonescimab in non-small cell lung cancer and other solid tumor settings. Ivonescimab is approved in China in combination with chemotherapy for patients with EGFR-mutated non-small cell lung cancer whose tumors have progressed following an EGFR-TKI based on the results of the HARMONi-A clinical trial.
Employees
265
Date Price Change Volume
26-11-06 $16.33 +15.08% 5,795,790
26-11-05 $14.19 -12.24% 5,940,026
26-11-04 $16.17 +2.34% 4,258,105
26-11-03 $15.80 +6.76% 6,045,173
26-11-02 $14.80 -7.67% 3,870,033
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
MarketScreener Ratings - Summit Therapeutics Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
12.22GBP
Average target price
22.33GBP
Spread / Average Target
+82.78%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Summit Therapeutics Inc.
  1. Stock Market
  2. Stocks
  3. SMMT Stock